PRIMARY STUDY
Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors.
Key Findings: Drugs targeting EC degradation offer therapeutic potential in the treatment of inflammatory bowel diseases. Furthermore, reduction of FAAH mRNA expression is involved in the pathophysiological response to colitis.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): Canada
Year of Pub: 2008
Cannabinoids Studied: Other Related Compounds
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2
